China Approves Albuvirtide: A Once-Weekly Injectable Entry Inhibitor

June 8, 2018

On 6 June 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.1

This is a rare example of an HIV treatment not being first approved in either the U.S. or Europe. Albuvitide is an HIV fusion inhibitor that works at an early stage of the HIV lifecycle by blocking attachment to CD4 cells. It has a similar structure and mechanism to an earlier HIV fusion inhibitor called enfuvirtide (T-20, Fuzeon) that was developed for people who had run out of treatment options.

Enfuvirtide was approved in 2003 but has been very rarely for the last ten years used because later drugs have become more effective and have an easier safety profile than the twice-daily subcutaneous injections it required.

Although there is little information about the results of the completed phase 3 studies that would have contributed to approval by the Chinese FDA, early results were presented at a UK conference in 2016.2,3

These reported good efficacy compared to the second-line treatment option that is currently available in China, an older protease inhibitor lopinavir/r. HIV positive people in China do not have access to integrase inhibitors that are now routinely recommended as first-line treatment in the U.S. and Europe, and that also overcome drug resistance to many other widely used HIV drugs.

From a safety persepective, albuvirtide was also not associated with the injection site reactions that limited the use of enfuvirtide.

Unfortunately the press release on approval in China still only refers to interim results from these studies.

Albuvirtide injection are marketed by Frontier Biotech with the trade name Aikening. There are plans to extend access outside of China, although further details have not been publicised.

In July 2017, the company announced a licensing agreement with with Rockerfeller University in the U.S. to coformulated albuvirtide with the broad neuralising monoclonal antibody 3BNC117.


  1. Frontier Biotech press release. Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV. (06 June 12018).
  2. Collins S. Once-weekly albuvirtide infusion: early results of T-20-like compound. HTB Novemebr 2016.
  3. Wu H et al. Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral- experienced adults with HIV-1: interim 48-week results from the randomised, controlled, phase 3, non-inferiority TALENT study. Glasgow Congress on HIV Therapy, 23-26 October 2016 (Glasgow 2016). Oral abstract O336. Webcast:
  4. Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody. (25 July 2017)

Related Stories

Is the World Ready for Long-Acting HIV Treatment?
Novel Drugs in the Pipeline for HIV Treatment

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.